1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > World Biosimilars/Follow-on-Biologics - Market Opportunities and Forecast, 2014 - 2020

Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth. The upcoming patent expiration for blockbuster drugs has revolutionized the aspect of commercialization whilst triggering a large scale adoption of biosimilars. Biosimilars industry is facing problems relating to production efficiency and quantity. The lack of economies of scale for small scale manufacturers and absence of regulatory guidelines in lucrative regions such as China, US are hindering the growth of biosimilars market. However, strong government initiatives pertaining to production and approval is a key factor that would eventually reduce the impact of these restraints over the forecast period. Global biosimilars/follow-on-biologics market accounted for an overall revenue of $2,552.0 million in 2014 and it is estimated to generate an approximate revenue of $26,551.3 million by 2020, registering a CAGR of 49.1% from 2015 to 2020. The product segment in the biosimilars market comprises of Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Colony Stimulating Factors and others. Biosimilars erythropoietin is the highest revenue generating biosimilars drug candidate owing to its high approval rate for commercialization. Interferon biosimilars are the fastest growing drugs in the biosimilars market. This growth is supplemented by the use of interferon biosimilars across a wide range of applications.The biosimilars applications market is segmented into blood disorders, oncology diseases, chronic and autoimmune diseases and growth hormone deficiency. The application of biosimilars in blood disease treatment is the highest revenue generating segment owing to the high-priced reference biologics and frequent application. However, biosimilars applications in autoimmune and chronic diseases exhibit the highest potential due to the changing off patent scenario.Based on geography, the biosimilars market is segmented across North America, Europe, Asia-Pacific and LAMEA. Asia Pacific and LAMEA exhibit a large scale demand for biosimilars due to the growing prevalence of chronic diseases in these regions. Collaboration with local players is a key opportunity for biosimilars in developing economies. Many companies such as, Amgen and Novartis are collaborating with Asian players to reach to the depth of the biopharmaceutical market. The absence of effective regulatory guidelines for product approval and commercialization limit the growth of the biosimilars market in North America. However, recent draft published by US FDA has approved first biosimilar in United States. This would eventually standardized the procedure of approval and commercialization of biosimilars in United States.This report provides a comprehensive market share analysis of leading companies and highlights the competition in the market. Product launch is the key strategy adopted by the leading player of biosimilars industry. The key companies profiled in this report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group). Key BenefitsThis report provides a detailed analysis of drivers and factors that limit the market expansionThe report provides a financial market forecast for the next eight years by considering the 2014 as the base year for evaluation. Comprehensive and quantitative data about changing market trends, competition and opportunities in biosimilars market are provided in the reportUse of Porters Five Forces model and SWOT analysis would help stakeholders in making strategic decisionsDeep dive analysis of leading market players and their key strategies, helps in better understanding the market dynamics Identification of key investment pockets in the biosimilars market would help the stakeholders in making informed decisionsKey DeliverablesGlobal biosimilars/follow-on-biologics market is categorized into product types, applications and geography.MARKET BY TYPESHuman growth hormoneErythropoietinMonoclonal antibodiesInsulinInterferonGranulocyte-Colony Stimulating FactorPeptideOthersMARKET BY APPLICATIONSBlood disordersOncology diseasesChronic and autoimmune diseasesGrowth hormone deficienciesOthersMARKET

BY GEOGRAPHY
North AmericaEuropeAsia-PacificLAMEA

Table Of Contents

World Biosimilars/Follow-on-Biologics - Market Opportunities and Forecast, 2014 - 2020
TABLE OF CONTENTSCHAPTER 1 INTRODUCTION1.1 Key Benefits1.2 Key Market Segment1.3 Research Methodology1.3.1 Primary Research1.3.2 Secondary Research1.3.3 Analyst tools and modelsCHAPTER 2 EXECUTIVE SUMMARY2.1 CXO perspective2.2 Market beyond: what to expect by 20252.2.1 Moderate growth scenario2.2.2 Rapid growth scenario2.2.3 Diminishing growth scenarioCHAPTER 3 MARKET OVERVIEW3.1 Market Definition3.2 Diverse approach of global regulators towards biosimilars3.3 Safety issues of biosimilar drugs3.4 Key Findings3.4.1 Top impacting factors3.4.2 Top winning strategies3.4.3 Top investment pockets3.5 Regulation and Reimbursement scenario3.5.1 Regulations in United States3.5.2 Regulations in Europe3.5.3 Regulation in Asia3.5.4 Comparison of Biosimilar medicine guidelines3.6 Emerging economies a hotspot for biosimilars market3.6.1 Brazil a treasure for the biosimilar manufacturers3.6.2 China the bulkmarket for biosimilars3.6.3 India an early adopter of biosimilars3.7 Porters five force analysis3.7.1 Higher bargaining of suppliers3.7.2 Moderate bargaining power of buyers3.7.3 Higher threats from substitutes due to lower switching cost3.7.4 Lower threats from new entrants due to technological and political barriers3.7.5 Higher competition among players3.8 Value chain analysis3.8.1 Primary activities3.8.2 Supportive activities3.9 Clinical trials3.9.1 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia3.9.2 Efficacy Study of Two Formulations of Erythropoietin3.9.3 Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology3.9.4 An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.13.10 Market Share analysis, 20143.11 Market Dynamics3.11.1 Drivers3.11.1.1 Growing pressure to reduce healthcare expenditure3.11.1.2 Various blockbusters going off patent3.11.1.3 High prevalence of chronic diseases among ageing population3.11.1.4 Favorable intervention from the developing economies3.11.1.5 Lower cost biosimilars drugs than original biologics3.11.2 Restraints3.11.2.1 High initial investment in research and development3.11.2.2 Stringent regulations in developed economies to restrict investment3.11.2.3 Medical Efficacy and Patient Safety3.11.3 Opportunities3.11.3.1 opportunities in Emerging economies3.11.3.2 Emergence of bio-betters drugsCHAPTER 4 GLOBAL MARKET BY TECHNOLOGY4.1 Monoclonal Antibodies (MAb) Technology4.1.1 Drivers4.2 Recombinant DNA Technology (rDNA technology)4.2.1 Drivers4.2.2 Restraints andamp; Opportunities4.3 Chromatography4.3.1 Protein sequencing4.3.2 Liquid chromatography (LC)4.3.3 Gas Chromatography (GC)4.3.4 Drivers4.4 Nuclear magnetic resonance (NMR) technology4.4.1 Drivers4.5 Electrophoresis4.5.1 Drivers4.5.2 Restraints andamp; Opportunities4.5.3 Gel Electrophoresis4.5.4 Capillary Electrophoresis4.6 MASS SPECTROMETRY4.6.1 Drivers4.6.2 Restraints4.7 Western Blotting4.7.1 Drivers4.8 Bioassay4.8.1 Drivers4.8.2 Restraints4.8.3 Techniques in BioassayCHAPTER 5 GLOBAL BIOSIMILARS MARKET BY PRODUCT5.1 Human Growth Hormone5.1.1 Key market trends5.1.2 Key growth factors and opportunities5.1.3 Market size andamp; forecast5.2 Insulin5.2.1 Key market trends5.2.2 Key growth factors and opportunities5.2.3 Market size andamp; forecast5.3 Interferon5.3.1 Key market trends5.3.2 Key growth factors and opportunities5.3.3 Market size andamp; forecast5.4 Granulocyte colony stimulating factor (G-CSF)5.4.1 Key market trends5.4.2 Key growth factors and opporunities5.4.3 Market size andamp; forecast5.5 Erythropoietin5.5.1 Key market trends5.5.2 Key growth factors and opportunities5.5.3 Market size andamp; forecast5.6 Monoclonal antibodies5.6.1 Key market trends5.6.2 Key growth factors and opportunities5.6.3 Market size andamp; forecast5.7 Peptides5.8 Others5.8.1 Key market trends5.8.2 Key growth factors and opportunityCHAPTER 6 GLOBAL MARKET BY APPLICATIONS6.1 Blood disorders6.1.1 Drivers6.1.2 Chemotherapy induce Anaemia6.1.2.1 Drivers6.1.2.2 RESTRAIN AND OPPORTINITIES6.1.3 Hemophilia6.1.4 Pulmonary embolism6.1.4.1 DRIVER6.2 Oncology diseases6.2.1 Driver6.2.2 Opportunities and restraints6.2.3 Lungs cancer6.2.4 Breast cancer6.2.5 Cervical cancer6.2.6 Colorectal cancer6.2.7 Prostate cancer6.2.8 Leukaemia6.3 Chronic and autoimmune diseases6.3.1 Diabetes6.3.1.1 Drivers6.3.2 Neutropenia6.3.3 Multiple sclerosis6.3.3.1 Drivers6.3.3.2 Restraints and opportunities6.3.4 Cystic Fibrosis6.3.5 Rheumatoid arthritis (RA)6.3.5.1 Drivers6.3.5.2 Restraints6.3.6 Acromegaly6.3.6.1 drivers6.3.7 Leprosy6.4 Growth hormone deficiency6.4.1 Drivers6.5 Others6.5.1 Gaucher disease6.5.2 OsteoporosisCHAPTER 7 GLOBAL MARKET BY SERVICES7.1 Contract Research and Manufacturing Services7.1.1 Drivers7.1.2 Restraints andamp; Opportunities7.2 Clinical trials7.2.1 Drivers andamp; Restraints7.2.2 Phase I7.2.3 Phase II7.2.4 Phase IIICHAPTER 8 GLOBAL BIOSIMILARS MARKET BY GEOGRAPHY8.1 North America8.1.1 Key market trends8.1.2 Key growth factors and opportunities8.1.3 Market size andamp; forecast8.2 Europe8.2.1 Key market trends8.2.2 Key growth factors and opportunities8.2.3 Market size andamp; forecast8.3 Asia-Pacific8.3.1 Key market trends8.3.1.1 India8.3.1.1.1 COMPETITIVE SCENARIO8.3.1.2 China8.3.1.2.1 COMPETITIVE SCENARIO8.3.1.3 Australia8.3.1.3.1 COMPETITIVE SCENARIO8.3.2 Key growth factors and opporunities8.3.3 Market size andamp; forecast8.4 LAMEA8.4.1 Key market trends8.4.2 Key growth factors and opportunities8.4.3 Market size andamp; forecastCHAPTER 9 KEY PRODUCTS AND RECENT ACTIVITIES9.1 US9.1.1 Hospira9.1.1.1 Recent Activities9.2 Europe9.2.1 Stada Arzneimittel AG9.2.1.1 Recent Activities9.2.2 Hexal AG9.2.3 Ratiopharm GmbH9.2.4 Bioton9.2.4.1 Recent Activities9.2.5 Sandoz GmbH9.2.5.1 Recent Activities9.3 India9.3.1 Dr.Reddyand#39;s Labs (DRL)9.3.1.1 Recent Activities9.3.2 Intas Pharmaceuticals Ltd.9.3.2.1 Recent Activities9.3.3 Wockhardt Limited9.3.3.1 Recent Activities9.3.4 Biocon Limited9.3.4.1 Recent Activities9.3.5 Shantha Biotechnics Limited9.3.5.1 Recent Activities9.3.6 Reliance Life Sciences9.4 Korea9.4.1 Dong-A Pharmaceutical Co., Ltd9.4.1.1 Recent Activities9.4.2 LG Life Sciences9.4.2.1 Recent Activities9.4.3 Celltrion Pharm, Inc.9.4.3.1 Recent Activities9.5 Others9.5.1 Teva Pharmaceutical Industries Ltd.9.5.1.1 Recent ActivitiesCHAPTER 10 COMPANY PROFILES10.1 Novartis (Sandoz)10.1.1 Company overview10.1.2 Company snapshot10.1.3 Operating business segment overview10.1.4 Business performance10.1.5 Key strategies10.1.5.1 Primary Strategies: Clinical Trials10.1.5.2 secondary Strategies: approval10.1.6 SWOT analysis10.2 Synthon Pharmaceuticals, Inc.10.2.1 Company overview10.2.2 Company snapshot10.2.3 Operating business segment overview10.2.4 Key strategies10.2.4.1 Primary Strategies: agreement10.2.4.2 secondary Strategies: clinical trials10.2.5 SWOT analysis10.3 Teva Pharmaceutical Industries Ltd.10.3.1 Company Overview10.3.2 Company Snapshot10.3.3 Operating business segment overview10.3.4 Business performance10.3.5 Key strategies10.3.5.1 Primary Strategies: approval10.3.5.2 secondary Strategies: clinical trials10.3.6 SWOT analysis10.4 LG Life Sciences10.4.1 Company overview10.4.2 Company snapshot10.4.3 Operating business segment overview10.4.4 Business performance10.4.5 Key strategies10.4.5.1 Primary Strategies: Collaboration10.4.6 SWOT analysis10.5 Celltrion10.5.1 Company overview10.5.2 Company snapshot10.5.3 Operating business segment overview10.5.4 Business Performance10.5.5 Key strategies10.5.5.1 Primary Strategies: approval10.5.6 SWOT analysis10.6 Biocon10.6.1 Company overview10.6.2 Company snapshot10.6.3 Operating business segment overview10.6.4 Business Performance10.6.5 Key strategies10.6.5.1 Primary Strategy: product launch10.6.5.2 secondary Strategy: clinical trial10.6.6 SWOT analysis10.7 Hospira10.7.1 Company overview10.7.2 Company snapshot10.7.3 Operating business segment overview10.7.4 Business performance10.7.5 Key strategies10.7.5.1 Primary Strategies: approval10.7.5.2 secondary Strategies: clinical trials10.7.6 SWOT analysis10.8 Merck Serono (Merck Group)10.8.1 Company overview10.8.2 Company snapshot10.8.3 Operating business segment overview10.8.4 Business performance10.8.5 Key strategies10.8.5.1 Primary Strategies: partnership and product launch10.8.6 SWOT analysis10.9 Biogen idec Inc.10.9.1 Company overview10.9.2 Company snapshot10.9.3 Operating business segment overview10.9.4 Business performance10.9.5 Key strategies10.9.5.1 Primary Strategies: agreement and joint venture10.9.6 SWOT analysis10.10 Genentech (Roche Group)10.10.1 Company overview10.10.2 Company snapshot10.10.3 Operating business segment overview10.10.4 Key strategies10.10.4.1 Primary Strategies: Investment and license10.10.5 SWOT analysisLIST OF FIGURESFIG. 1 TOP FACTORS IMPACTING BIOSIMILARS MARKET (2014-2020)FIG. 2 TOP WINING STRATEGIES FOR BIOSIMILARS MARKET DURING (2010-2015)FIG. 3 TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENTS (2010-2015)FIG. 4 TOP INVESTMENT POCKETS OF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET PRODUCTS, 2014-2020FIG. 5 KEY ACHIEVEMENTS FOR BIOSIMILAR REGULATORS (2010)FIG. 6 REGULATORY FRAMEWORK FOR BIOSIMILAR PRODUCTS IN CHINAFIG. 7 PORTERS FIVE FORCE ANALYSIS OF BIOSIMILARS MARKETFIG. 8 VALUE CHAIN ANALYSIS OF BIOSIMILARS MARKETFIG. 9 IMPACT ANALYSIS OF STAKEHOLDERS INVOLVED IN PRIMARY ACTIVITIES (2014-2020)FIG. 10 MARKET SHARE ANALYSIS OF BIOSIMILARS MARKET (2014)FIG. 11 IMPACT ANALYSIS OF PRODUCT MARKET SEGMENTS (2014, 2020-2025)FIG. 12 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 andamp; 2030)FIG. 13 IMPACT ANALYSIS OF APPLICATION MARKET SEGMENTS (2014-2020-2025)FIG. 14 IMPACT OF REGULATION ON VARIOUS GEOGRAPHIES, 2012FIG. 15 NET REVENUE GENERATION BY GEOGRAPHY (2013)FIG. 16 NET REVENUE GENERATION BY BUSINESSES (2013)FIG. 17 SWOT ANALYSIS OF NOVARTIS (SANDOZ)FIG. 18 SWOT ANALYSIS OF SYNTHON PHARMACEUTICALSFIG. 19 NET REVENUE GENERATION BY GEOGRAPHY (2013)FIG. 20 NET REVENUE GENERATION BY BUSINESSES (2013)FIG. 21 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.FIG. 22 NET REVENUE GENERATION (2011-2013)FIG. 23 SWOT ANALYSIS OF LG LIFE SCIENCESFIG. 24 NET PROFIT DURING 2011-2013FIG. 25 SWOT ANALYSIS OF CELLTRIONFIG. 26 REVENUE GENERATED BY BUSINESS UNITS (2013)FIG. 27 SWOT ANALYSIS OF BIOCONFIG. 28 NET SALES BY GEOGRAPHY (2013)FIG. 29 NET SALES BY BUSINESS UNITS (2013)FIG. 30 SWOT ANALYSIS OF HOSPIRAFIG. 31 NET SALES BY GEOGRAPHY (2013)FIG. 32 NET SALES BY BUSINESS UNITS (2013)FIG. 33 SWOT ANALYSIS OF MERCK SERONOFIG. 34 NET SALES BY GEOGRAPHY (2013)FIG. 35 NET SALES BY BUSINESS UNITS (2013)FIG. 36 SWOT ANALYSIS OF BIOGEN IDEC INC.FIG. 37 SWOT ANALYSIS OF GENENTECHLIST OF TABLESTABLE 1 BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)TABLE 2 BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)TABLE 3 BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)TABLE 4 BIOSIMILARS GUIDELINES ADOPTED BY REGIONSTABLE 5 COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)TABLE 6 BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)TABLE 7 OFF GOING PATENTS 2013-2016TABLE 8 PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)TABLE 9 BIOSIMILAR DEVELOPMENT STATUS (2013)TABLE 10 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2014-2020 ($MILLION)TABLE 11 PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)TABLE 12 PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)TABLE 13 GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)TABLE 14 PATENTS APPROVED FOR INSULIN (BIOLOGICS)TABLE 15 GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)TABLE 16 PATENTS APPROVED FOR INTERFERON (BIOLOGICS)TABLE 17 PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)TABLE 18 GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 19 PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)TABLE 20 GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 21 PATENTS STATUS FOR ERYTHROPOIETIN (BIOLOGICS)TABLE 22 PATENT EXPIRATION STATUS FOR ERYTHROPOIETIN DURING 2014-2020 (BIOLOGICS)TABLE 23 GLOBAL ERYTHROPOIETIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 24 DRUG PATENT EXPIRATION FOR MONOCLONAL ANTIBODIES (BIOLOGICS)TABLE 25 PATENT EXPIRATION STATUS FOR MONOCLONAL ANTIBODIES DURING, 2014-2020 (BIOLOGICS)TABLE 26 GLOBAL MAB BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 27 GLOBAL PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014 -2020 ($MILLION)TABLE 28 HIRUDIN BIOSIMILAR CANDIDATE STATUSTABLE 29 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)TABLE 30 GLOBAL BLOOD DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 31 GLOBAL ONCOLOGY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 32 GLOBAL CHRONIC AND AUTOIMMUNE DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 33 GLOBAL GROWTH HORMONE DEFICIENCY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 34 GLOBAL OTHER DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 35 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 36 NORTH AMERICA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATION, 2014-2020 ($MILLION)TABLE 37 BIOSIMILARS COMMERCIALLY AVAILABLE IN EUROPEAN UNIONTABLE 38 EUROPE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)TABLE 39 ASIA-PACIFIC BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)TABLE 40 LAMEA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry in Europe

  • November 2016
    42 pages
  • Biosimilar  

  • Europe  

View report >

Pathology Statistics in Canada

  • October 2016
    2 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Bioprocessing Industry

3 months ago

Biosimilar Statistics

3 months ago

Biosimilar Statistics

3 months ago

Related Market Segments :

Biosimilar

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.